Late conversion of tacrolimus to sirolimus in a prednisone-free immunosuppression regimen in renal transplant patients

Clinical Transplantation

Volumn 24, Issue 2, 2010, Pages 199-206

  Chhabra, Darshika ^a   Grafals, Monica ^a   Cabral, Brian ^a   Leventhal, Joseph ^a   Parker, Michele ^b   Gallon, Lorenzo ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitors; Prednisone free; Sirolimus

Indexed keywords

ALEMTUZUMAB; CLOTRIMAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ACNE; ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY GRAFT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MYCOSIS; PRIORITY JOURNAL; PROTEINURIA; RASH; RISK ASSESSMENT; SINGLE DRUG DOSE; VIRUS INFECTION;

ADULT; ANTIBIOTIC PROPHYLAXIS; FEASIBILITY STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS;

EID: 77952900950     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01047.x     Document Type: Article

References (27)

1. Chapman JR, Nankivell BJ. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? Nephrol Dial Transplant 2006, 21:2060.
2. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998, 66:1736.
3. Knight RJ, Kahan BD. The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity? Kidney Int 2006, 70:994.
4. Larson TS, Dean PG, Stegall MD. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006, 6:514.
5. Flechner SM, Goldfarb D, Solez K. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007, 83:883.
6. Pearson TC, Mulgaonkar S, Patel A. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the spare-the-nephron (STN) trial. 2008, 8th American Transplant Congress, Toronto, Canada, Blackwell Publishing
7. Lebranchu Y, Etienne I, Touchard G. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF). 2007, Annual American Transplant Congress, San Francisco, CA, Blackwell Publishing
8. Gallon LG, Winoto J, Leventhal JR, Parker MA, Kaufman DB. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006, 1:1029.
9. Amundsen B, Gallon LG, Kaufman D, Walker J, Leventhal JR. Steroid voidance and delayed introduction of tacrolimus using alemtuzumab induction in kidney transplantation: five year follow-up. 2007, American Transplant Congress, San Francisco, CA
10. Gaspari F, Ferrari S, Stucchi N. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004, 4:1826.
11. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002, 2:551.
12. Vitko S, Margreiter R, Weimar W. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005, 5:2521.
13. Merion RM, White DJG, Thiru S, Evans DB, Calne RY. Cyclosporine - 5 years experience in cadaveric renal-transplantation. N Engl J Med 1984, 310:148.
14. Ponticelli C, Minetti L, Dipalo FQ. The milan clinical-trial with cyclosporine in cadaveric renal-transplantation - a 3-year follow-up. Transplantation 1988, 45:908.
15. Sinclair NRS. Low-dose steroid-therapy in cyclosporine-treated renal-transplant recipients with well-functioning grafts. CMAJ 1992, 147:645.
16. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000, 70:1352.
17. Ahsan N, Hricik D, Matas A. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Transplantation 1999, 68:1865.
18. Gallon L, Gagliardini E, Benigni A. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (campath-1H). Clin J Am Soc Nephrol 2006, 1:539.
19. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction - long-term results. Am J Transplant 2005, 5:2539.
20. Matas AJ, Kandaswamy R, Gillingham KJ. Prednisone-free maintenance immunosuppression - a 5-year experience. Am J Transplant 2005, 5:2473.
21. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006, 82:1153.
22. Watson CJE, Firth J, Williams PF. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005, 5:2496.
23. Gelens M, Christiaans MHL, van Heurn ELW, van den Berg-Loonen EPM, Peutz-Kootstra CJ, van Hooff JP. High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation 2006, 82:1221.
24. Wu ZH, Bensinger SJ, Zhang JD. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004, 10:87.
25. Pearl JP, Parris J, Hale DA. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005, 5:465.
26. Salama AD, Najafian N, Clarkson MR, Harmon WE, Sayegh MH. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 2003, 14:1643.
27. Letavernier E, Bruneval P, Mandet C. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007, 2:326.